10-Q: Sonoma Pharmaceuticals Reports Q3 2025 Results: Revenue Up, Internal Control Weaknesses Persist

Sonoma Pharmaceuticals reports increased revenue for Q3 2025 but acknowledges ongoing material weaknesses in internal control over financial reporting.

Summary

• Sonoma Pharmaceuticals reported an increase in revenue for the three and nine months ended December 31, 2024, but also disclosed material weaknesses in its internal control over financial reporting.
• Revenue for the three months ended December 31, 2024, increased by 14% to $3.564 million, compared to $3.138 million for the same period in 2023.
• Revenue for the nine months ended December 31, 2024, increased by 13% to $10.534 million, compared to $9.296 million for the same period in 2023.
• The company reported a net loss of $928,000 for the three months ended December 31, 2024, compared to a net loss of $866,000 for the same period in 2023.
• The net loss for the nine months ended December 31, 2024, was $2.681 million, compared to a net loss of $3.768 million for the same period in 2023.
• The company's accumulated deficit amounted to $197.030 million as of December 31, 2024.
• The company acknowledges material weaknesses in internal control over financial reporting, specifically a lack of separation of duties.
• Management is implementing remediation measures, including improved monitoring, hiring experienced personnel, and providing internal controls training.
• The company effected a reverse stock split of its common stock on August 29, 2024, at a ratio of 20:1.
• The company believes it has access to additional capital resources but acknowledges uncertainty about securing financing on acceptable terms.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While revenue increased, the company is still operating at a loss and has identified material weaknesses in internal controls, raising concerns about its financial stability and future prospects. The going concern warning further contributes to the negative sentiment.

Positives

• Revenue increased for both the three and nine months ended December 31, 2024.
• Gross profit increased by $283,000 for the nine months ended December 31, 2024, primarily due to an increase in revenue.
• Net cash provided by operating activities during the nine months ended December 31, 2024 was $7,000.
• The company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means.

Negatives

• The company reported a net loss for both the three and nine months ended December 31, 2024.
• The company has an accumulated deficit of $197.030 million as of December 31, 2024.
• The company acknowledges material weaknesses in internal control over financial reporting.
• There is substantial doubt about the company's ability to continue as a going concern within one year after the date that the financial statements are issued.

Risks

• The company's ability to secure additional capital is uncertain.
• The company's reliance on certain key customers for a significant portion of its revenues poses a risk.
• The company is exposed to risk from foreign currency devaluation.
• The company faces a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest.
• Failure to successfully transition European products to the new Medical Device Regulation could result in product withdrawals.
• New or increased tariffs on goods imported into the United States, particularly tariffs on products manufactured in Mexico, could adversely affect the business.

Future Outlook

The company believes it has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the company cannot provide any assurance that new financings will be available on commercially acceptable terms, if needed.

Management Comments

• Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that new financings will be available on commercially acceptable terms, if needed.
• Management, with oversight from the Audit Committee of our Board of Directors, is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.

Industry Context

The company operates in the healthcare industry, specifically focusing on wound care, dermatology, eye care, and animal health. The report highlights the company's efforts to expand its product lines and distribution networks in various geographic regions. The discussion of tariffs and trade agreements reflects the broader economic and political factors affecting global businesses.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific benchmarks for revenue growth, profitability, or operational efficiency within the hypochlorous acid product market, a comprehensive assessment is not possible.
• A comparison would require data from competitors such as companies specializing in wound care, dermatology products, or animal health solutions, including specifics on their financial performance and market share.
• Additionally, information on the typical costs associated with regulatory compliance, such as the Medical Device Regulation in Europe, would be needed to evaluate Sonoma Pharmaceuticals' performance in this area.

Stakeholder Impact

• Shareholders face uncertainty due to the company's losses, accumulated deficit, and material weaknesses in internal control.
• Employees may be affected by potential cost-cutting measures if the company is unable to secure additional capital.
• Customers may experience disruptions if the company faces financial difficulties or is unable to maintain regulatory compliance.
• Suppliers and creditors face increased risk due to the company's going concern warning.

Next Steps

• Management will continue to implement remediation measures to address the material weaknesses in internal control over financial reporting.
• The company will continue to monitor statements made and actions taken by the U.S. government regarding tariffs on goods imported into the U.S. from Mexico, Canada, and other countries.
• The company will continue to evaluate whether to conduct the additional studies necessary to transition certain products to the new Medical Device Regulation.

Key Dates